You can now read 5 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

Biogen Idec seeks OK for hemophilia B treatment

Biogen Idec Inc. has applied to the Food and Drug Administration for approval to market a new treatment for hemophilia B, the Weston biotechnology company said Friday.

Hemophilia B is a rare inherited disease that keeps patients’ blood from clotting and can cause bleeding, joint damage, and life-threatening hemorrhages. Biogen Idec said it submitted its biologics license application to the FDA recently and expects a decision some time this year. It is the first product in a class of clotting therapies the company is developing.

Continue reading below

Biogen Idec said it is on track to submit a similar application for a drug to treat another form of the disease, hemophilia A, in the first quarter of this year.

The company, a global leader in multiple sclerosis drugs, said Thursday it was ending development of an experimental drug for Lou Gehrig’s disease after the drug proved ineffective in a late-phase clinical trial.

Robert Weisman can be reached at weisman@globe.com.
Loading comments...
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com
Already a subscriber?
Your city. Your stories. Your Globe.
Yours FREE for two weeks.
Enjoy free unlimited access to Globe.com for the next two weeks.
Limited time only - No credit card required!
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.
Thanks & Welcome to Globe.com
You now have unlimited access for the next two weeks.
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.